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Background. Although stimulants have long been touted as treatments for attention deﬁcit disorder with or without hyperactivity
(ADHD), in recent years, increasing concerns have been raised about the cardiovascular safety of these medications. We aimed to
prove if measurements of autonomic function with time domain analysis of heart rate variability (HRV) in 24-hour Holter ECG
are useful to predict the risk of sudden cardiac death in ADHD children and adolescents. Methods. We analysed HRV obtained
from children with the diagnosis of ADHD prior to (N = 12) or during medical therapy (N = 19) with methylphenidate (MPH),
aged 10.8 ± 2.0 years (mean ± SD), who were referred to our outpatient Paediatric Cardiology Clinic to rule out heart defect.
As a control group, we compared the HRV data of 19 age-matched healthy children without heart defect. Results.A v e r a g eH R V
parameters from 24-hour ECG in the ADHD children prior to MPH showed signiﬁcant lower values compared to healthy children
with respect to rMSSD (26 ± 4msversus44± 10ms, P ≤ 0.0001) and pNN50 (6.5 ± 2.7% versus 21.5 ± 9.0%, P ≤ 0.0001).
These values improved in MPH-treated children with ADHD (RMSSD: 36 ± 8ms; pNN50: 14.2 ± 6.9%). Conclusion. Children
who suﬀer from ADHD show signiﬁcant changes in HRV that predominantly reﬂects diminished vagal tone, a well-known risk
factor of sudden cardiac death in adults. In our pilot study, MPH treatment improved HRV.
1.Introduction
Reports of sudden death among children and adolescents
receiving stimulant medications for treatment of attention
deﬁcit disorder with or without hyperactivity (ADHD)
have raised concerns about the safety of these agents.
In the last two years, many articles have been published
about the cardiovascular safety of stimulant medication [1–
6]. There are very few reports about clinically measured
cardiovasculardatainADHDchildrenandadolescents[7,8].
It remains controversial if treatment of ADHD children with
stimulants reduces or increases the risk of sudden death
(SD) [6]. The assumption that stimulant-treated ADHD
patients are at higher risk for SD is based on either (a) the
proarrhythmogenic eﬀects of these agents, which are closely
related members of the class of sympathomimetic amines,
or (b) complicated statistical models with estimated data
from uncertain data bases like the Adverse Event Reporting
System. Due to the rarity of SD in pediatric populations,
compared to adults, it is extremely diﬃcult to establish a
reliable model to predict sudden cardiac arrest in children
and adolescents. It is the search for the needle in the haystack
[2]. For the assessment of cardiac risk, there is no doubt that
an accurate history and physical examination are important,
but ambiguities in current screening recommendations with
respect to electrocardiogram assessment show the lack of
suﬃcient surrogate measurements [9].
The autonomic nervous system plays an important role
in sudden cardiac death [10]. Twenty-four-hour Holter
recordings in post myocardial infarction (MI) in adult2 ISRN Pharmacology
patients showed that depressed heart rate variability (HRV)
was a signiﬁcant predictor of mortality after adjusting
for clinical and demographic features, including ejection
fraction. These studies were further conﬁrmed by others
studying post-MI patients, who showed that impaired HRV
was an independent predictor of cardiac mortality only
within 6 months of MI and seemed to improve over time
[10, 11]. HRV is also reduced in survivors of sudden cardiac
deathnotassociatedwithcoronaryarterydiseaseandmaybe
related to the decrease of parasympathetic tone [12].
Measurement of heart rate variability in 24-hour Holter
ECG is completely noninvasive. Normal values are available
for children [13] and adults [14].
In our pilot study, we investigate whether measurements
of autonomic function with time domain analysis of HRV in
24-hour ECG are useful to determine risk factors for sudden
cardiac death in patients with ADHD.
2. Methods
2.1. Subjects. We analysed HRV obtained from children with
the diagnosis of ADHD prior to (N = 12) or during medical
therapy (N = 19) with methylphenidate (MPH), aged
10.8 ± 2.0 years. From August 2005 to Mach 2010, children
with the diagnosis of ADHD were referred to our Paediatric
Cardiology Outpatient Clinic for cardiology assessment.
T h em e a nd a i l yM P Hd o s a g eo f1 9c h i l d r e no ns t i m u l a n t
medication was 0.8 ± 0.4mg/kg/day (9 children received
methylphenidate extended release). All children received a
standard 12-lead ECG, an echocardiogram, and 24-hour
Holter ECG. As a control group, we compared the HRV data
of19age-matchedhealthychildren,whowerereferredtorule
outcardiacdefectsduetoheartmurmur,palpitation,orchest
pain.
2.2. Processing and Analysis of 24-Hour Holter Recordings.
Autonomic control of cardiovagal function was assessed by
time domain analysis of 24-hour ambulatory digital record-
ings of the electrocardiogram using a two-channel Holter
monitor (Pathﬁnder, Spacelabs). All Holter recordings were
reviewed by the same cardiologist and were edited to validate
the system’s QRS labelling. Measures of HRV were calculated
employing only normal to normal intervals. Numbers of
pairs of adjacent normal beat (NN) intervals diﬀering by
more than 50ms were given as the percentage of the total
number of all NN intervals during 24 hours (pNN50).
Measurement and physiological interpretation of HRV
parameters were performed according to the standards of
the Task Force of the European Society of Cardiology and
the North American Society of Pacing and Electrophysiology
[15].RMSSD,pNN50,andheartratereﬂectpredominantlya
responsetochangesin vagaltone. SDNNis duallyinﬂuenced
by cholinergic and adrenergic activity, as well as other
physiological inputs.
2.3. Exclusion Criteria. The data of 5 children with ADHD
and more than 20 premature ventricular contractions per
hour were excluded.
2.4. Informed Consent. After adequate explanation of the
purpose of the study, informed consent was obtained from
the parents. The study protocol was approved by the local
ethic committee before the start of the investigation.
2.5. Statistical Analysis. A l lr e s u l t sa r er e p o r t e da sm e a n±
standard deviation. Because all variables were normally
distributed, a parametric test was used. Diﬀerences between
the controls and ADHD patients with and without MPH
treatment were tested with an unpaired t-test with Welch’s
correction. For all parameters, a value of P<0.05 was
considered statistically signiﬁcant. The data analyses were
performed using Excel 2003 (Microsoft, USA) and Prism
(GraphPad software Inc., USA).
3. Results
All patients were in sinus rhythm and had a normal
echocardiogram. As shown in Table 1, there is no signiﬁcant
statistical diﬀerence with respect to age between the ADHD
patients (with or without MPH) and the healthy control
group. Average HRV parameters from the 24-hour ECG in
the ADHD children without MPH show signiﬁcantly lower
heart rate variability compared to the healthy children with
respect to rMSSD (26 ± 4m sv e r s u s4 4± 10ms, P ≤ 0.0001)
and pNN50 (6.5 ± 2.7% versus 21.5 ± 9.0%, P ≤ 0.0001).
TheseparametersimprovesigniﬁcantlyafterMPHtreatment
(rMSSD: 36 ± 8ms; pNN50: 14.2±6.9%). These parameters
predominantly reﬂect changes in vagal tone. Due to these
autonomic changes, untreated children with ADHD had a
higher mean heart rate compared to healthy children (94 ±
7/min versus 85 ± 10/min). Average SDNN in ADHD
patients wasnot signiﬁcantly diﬀerent from healthychildren.
4. Discussion
In our pilot study, we measured time domain values of heart
rate variability in 24-hour Holter ECGs in children with
ADHD. Our data demonstrate signiﬁcantly lower rMSSD
and pNN50 values and elevated heart rates in nonpharma-
cologically treated ADHD children and adolescents. These
parameterspredominantlyreﬂectdiminishedparasympathic
activity. If we adjust the data of our 12 untreated children
with ADHD in the ﬁgure of published rMSSD and pNN50
normal values in children [13] and adults [14]( Figure 1), we
notice that these data are not only far away from the mean
values for healthy children between 8 and 13 years but also
near to the dashed line, which represents cutoﬀ for increased
risk of sudden cardiac death in adults. Furthermore, we
demonstrate signiﬁcant improvement and almost normal
values of rMSSD and pNN50 after treatment with MPH.
Our data indicate the lack of physiological maturation
of autonomic function with low parasympathetic tone
in children with ADHD at the average age of 10 years.
From a pathophysiological point of view, patients with low
parasympathic activity have an increased risk for sudden
cardiac death, independent of other risk factors. This might
explain the increased baseline risk in these patients observedISRN Pharmacology 3
Table 1: Heart rate variability in healthy children (n = 19), children with ADHD untreated (n = 12) and treated with methylphenidate
(MPH) (n = 19).
Mean ± SD P 1v e r s u s2 P 2v e r s u s3 P 1v e r s u s3
Age (years)
Healthy 10.8 ± 3.5
ADHD 10.8 ± 2.0 P = ns P = ns P = ns
ADHD + MPH 10.6 ± 2.8
Heart rate (/min.)
Healthy 85 ± 10
ADHD 94 ± 7 P = 0.003 P = 0.04 P = ns
ADHD + MPH 90 ± 6
SDNN (ms)
Healthy 146 ± 30
ADHD 136 ± 41 P = ns P = ns P = ns
ADHD + MPH 151 ± 25
rMSSD (ms)
Healthy 44 ± 10
ADHD 26 ± 4 P<0.0001 P = 0.0001 P = 0.008
ADHD + MPH 36 ± 8
pNN50 (%)
Healthy 21.5 ± 9.0
ADHD 6.5 ± 2.7 P = 0.0001 P = 0.0002 P = 0.008
ADHD + MPH 14.2 ± 6.9
Values are given in mean ± SD. Probability of diﬀerence using student t-test; signiﬁcant values are in bold; SDNN: standard deviation of all NN intervals;
rMSSD: square root of the mean of the sum of the squares of diﬀerences between adjacent NN intervals; pNN50: number of pairs of adjacent NN intervals
diﬀering by more than 50ms divided by the total number of all NN intervals.
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Figure 1: Relationship between age and the HRV parameter rMSSD and pNN50 in healthy subjects, published by Massin et al. [13]a n d
Umetani et al. [14]. These parameters reﬂect parasympathetic activity of the autonomic nervous system. Solid lines: ﬁtted regression lines
± 1SD line in childhood. Dashed line: published cutoﬀs for increased risk of mortality from sudden cardiac death. : Values of 12 children
with ADHD and : 19 children with ADHD treated with methylphenidate.4 ISRN Pharmacology
in former studies [3]. However, higher rMSSD and pNN50
values in our children with ADHD who were treated with
MPH indicate a higher vagal tone, which is considered as
protectiveforsuddencardiacdeath[10].Ourdatasupplythe
ﬁrst feasible explanation why recently published population-
based cohort studies showed an apparent protective asso-
ciation and not an increased risk of serious cardiovascular
events in stimulant users [16–18]. These results need to be
proven by randomized prospective studies.
In conclusion, our data provides new information about
autonomic dysfunction in children with ADHD and the
inﬂuence of MPH therapy, which could be important for
risk stratiﬁcation for sudden cardiac death in this patient
cohort. In contrast to theoretical speculations that MPH
treatment may increase the risk of sudden death in chil-
dren with ADHD, our data demonstrate improvement of
heart rate variability in Holter ECG. This indicates higher
parasympathetic activity induced by MPH, which may be
beneﬁcial with respect to the risk of sudden cardiac death in
ADHD children and adolescents.
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